PDCD1 and neoplasm: Therefore, molecules capable of targeting PD-1 (Nivolumab and Pembrolizumab), PD-L1 (Atezolizumab, Durvalumab), and CTLA-4 (Nivolumab, Ipilimumab, Tremelimumab-actl), known as immune checkpoint inhibitors, stimulate the immune response against tumor cells [119].